Huakang Biomedical Holdings Company Limited (HKG:8622)

Market Cap	215.20M
Revenue (ttm)	28.24M
Net Income (ttm)	-5.20M
Shares Out	500.47M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	688,000
Average Volume	1,615,200
Open	0.4150
Previous Close	0.4150
Day's Range	0.4100 - 0.4350
52-Week Range	0.1150 - 0.6500
Beta	0.65
RSI	67.79
Earnings Date	Nov 14, 2025

About HKG:8622

Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biom...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 91
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8622

Financial Performance

In 2024, HKG:8622's revenue was 25.36 million, an increase of 2.96% compared to the previous year's 24.63 million. Losses were -4.16 million, -28.09% less than in 2023.

Financial numbers in CNY